Implications of Biological and Procedural Factors of 18-f FDG Uptake by Normal Organs and Neoplastic Lesions

ConditionOncologic Diseases

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age1-90

Sponsormahenoor alaa eldeen naem

About this trial

To evaluate implications of biological and procedural factors of 18-f FDG PET/CT uptake on normal organs and neoplastic lesions.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

cancer patients referred to nuclear medicine unit

Disqualifiers

patients with increased FDG uptake associated with non malignant causes such as diffuse bone marrow FDG uptake or lung infection or patients with extensive metastasis in target organs

Trial population

all cancer patients

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

18 FDG (Fludeoxyglucose 18F)
Radiation
18-f FDG

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

PET/CT scan on cancer patient will be performed to evaluate the biological and procedural factors of 18-f FDG uptake by multiple normal organs and neoplastic lesions using Standardized uptake values

SUV mean , suv peak and suv max

Time frame

2 years

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

mahenoor alaa eldeen naem

Lead sponsor

Assiut University

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: